Gerlier Skeletal Asymmetry 4-Pathway Model

Certainty: 0.10. This model was proposed by Colette Marie Gerlier (2026-07-21, personal communication). The entire cascade from skeletal asymmetry β†’ multi-organ dysautonomia has zero direct ME/CFS evidence. Included because (a) it generates specific, low-cost, falsifiable predictions (shoe lift, EOS radiography, COMPASS-31), (b) if validated, a simple mechanical intervention could be disease-modifying, and (c) its 4-pathway convergence on the dopaminergic node provides specific diagnostic logic. Consequence for this entire section: The 2-week shoe lift trial is the highest-yield probe. If positive (reduced standing PEM, improved COMPASS-31), a mechanical trigger IS contributing. If negative, asymmetry may be non-contributory β€” direct attention to biochemical/autoimmune hypotheses. Origin: Gerlier 2026-07-21, personal communication; pathway tracing by mechanistic inference.

1 Pathway 1: Compensatory Muscle Overuse β†’ Anaerobic Metabolism

1.1 Cascade: Skeletal asymmetry β†’ muscle overuse β†’ ATP drain β†’ PEM

Cascade:

  • Fixed skeletal asymmetry (rotoscoliosis, pelvic obliquity >10 mm, DAMI/ILMI)
  • Chronic compensatory postural muscle overuse β†’ elevated basal energy consumption (~5–10%)
  • Continuous low-grade ATP drain β†’ breached critical ATP threshold (WASF3–DRP1 Convergence: Two Routes to the Same Mitochondrial Failure)
  • Anaerobic shift, intracellular Na⁺ overload, NCX1 reverse, mitochondrial Ca²⁺ overload
  • PEM from trivial activity

Step G1a: Fixed skeletal asymmetry (mechanical trigger)

  • Intercept: Shoe lift (if LLD); Custom orthotics; Postural physiotherapy
ImportantFinding: Shoe lift reduces standing/walking PEM within days β€” skeletal asymmetry directly driving PEM

Strongest evidence for the Gerlier hypothesis in an individual: mechanical correction of asymmetry reduces the ATP drain from compensatory muscle overuse, confirming the mechanical trigger is functionally significant.

Certainty
Low to Medium
Level of action
Partial root cause β€” mechanical asymmetry
ImportantFinding: Shoe lift does NOT reduce PEM β€” asymmetry not functionally contributing

Asymmetry may be non-contributory to PEM, or compensatory postural patterns have become fixed/learned and no longer reverse with acute mechanical correction.

Certainty
Low
Level of action
Symptom management β€” non-contributory finding

Step G1b: Compensatory muscle overuse β†’ ATP drain

  • Intercept: CoQ10 (ubiquinone/ubiquinol; electron transport chain cofactor), creatine (phosphocreatine energy buffer), L-carnitine (fatty acid shuttle into mitochondria) β€” mitochondrial support; NMN/NR (nicotinamide mononucleotide/nicotinamide riboside; NAD⁺ precursors); LDN (low-dose naltrexone; TLR4 antagonist)
ImportantFinding: CoQ10/creatine reduces PEM when shoe lift does NOT β€” ATP production is the bottleneck

The rate-limiting step is mitochondrial ATP production capacity, not ATP consumption rate from compensatory muscle overuse. Mitochondrial support (CoQ10, creatine) compensates for inadequate energy synthesis.

Certainty
Low
Level of action
Partial root cause β€” mitochondrial ATP production deficit
ImportantFinding: Shoe lift works but CoQ10 does NOT β€” asymmetry-driven demand is the bottleneck

Mitochondrial capacity is adequate; the problem is excessive ATP consumption from compensatory postural muscle overuse driven by skeletal asymmetry. Mechanical correction addresses the root cause.

Certainty
Low
Level of action
Partial root cause β€” mechanical demand excess

Step G1c: Anaerobic shift / Na⁺-Ca²⁺ cascade

2 Pathway 2: Sympathetic Chain Irritation β†’ Multi-Organ Dysautonomia

2.1 Cascade: Rotoscoliosis β†’ sympathetic chain compression β†’ organ dysfunction

Cascade:

  • Rotoscoliosis/vertebral rotation β†’ mechanical compression of sympathetic chain (T1–L2)
    1. Acute compression β†’ irritative firing β†’ hyperadrenergic state
    1. Chronic compression β†’ conduction block β†’ denervation hypersensitivity
    1. Organ-specific dysfunction: T5–T9 β†’ gastroparesis, T10–L1 β†’ RAAS dysregulation, T1–T4 β†’ cardiac

Step G2a: Sympathetic chain compression

  • Intercept: Shoe lift / postural correction; Osteopathic manipulation (CAUTION β€” unstable CCI)
ImportantFinding: Shoe lift improves COMPASS-31 β€” sympathetic chain compression driving autonomic dysfunction

Mechanical correction of rotoscoliosis reduces compression of the sympathetic chain, confirming that autonomic dysfunction is mechanically driven (Gerlier Pathway 2-specific evidence).

Certainty
Low
Level of action
Partial root cause β€” mechanical sympathetic compression

Step G2b: Organ-specific dysautonomia

  • Intercept: Pyridostigmine (acetylcholinesterase inhibitor; peripheral cholinergic) β€” enhances remaining cholinergic tone in GI; Domperidone (peripheral D2 receptor antagonist; prokinetic); Midodrine (Ξ±1-adrenergic receptor agonist; vasoconstrictor) for cardiac
  • Differential: Cardiac-predominant vs. GI-predominant vs. renal maps to specific vertebral levels of compression.

3 Pathway 3: Mechanical Nerve Compression β†’ Pain, Paresthesia

3.1 Cascade: Fascial tension β†’ nerve compression β†’ positional neuropathic pain

Cascade:

  • Asymmetric fascial tension β†’ altered nerve glide planes
  • Compression at mechanical pinch points (lateral femoral cutaneous, sciatic, pudendal)
  • Chronic low-grade compression neuropathy β†’ fluctuating paresthesia, positional allodynia

Step G3a: Mechanical nerve compression at pinch points

  • Intercept: Shoe lift / postural correction; Nerve glide exercises; Targeted nerve blocks (diagnostic)
ImportantFinding: Shoe lift reduces paresthesia/allodynia β€” compression neuropathy is mechanically reversible

Response to postural correction confirms that asymmetric fascial tension is causing mechanical compression at nerve pinch points. The neuropathy is positionally driven and reversible with mechanical correction.

Certainty
Low
Level of action
Symptom management β€” mechanically reversible neuropathy

Step G3b: Central sensitization amplification

  • Intercept: LDN (low-dose naltrexone; TLR4 antagonist); Low-dose amitriptyline (5–10 mg; tricyclic antidepressant at microdose); Gabapentin/pregabalin (Ξ±2Ξ΄ calcium channel ligands; gabapentinoids)
ImportantFinding: LDN works for pain but shoe lift does NOT β€” central sensitization is the bottleneck

Peripheral mechanical trigger correction alone is insufficient; the pain is primarily maintained by central sensitization (microglial activation, TLR4 signaling). Treatment should target central mechanisms.

Certainty
Low
Level of action
Partial root cause β€” central sensitization
ImportantFinding: Shoe lift + LDN works better than either alone β€” dual pathology

Both a peripheral mechanical trigger AND a central sensitization amplifier contribute to pain. Combined mechanical correction and anti-neuroinflammatory treatment address both layers.

Certainty
Low
Level of action
Partial root cause β€” dual mechanical and central pathology

4 Pathway 4: Cervical Aging Spiral β†’ Functional CCI + Proprioceptive Degradation

4.1 Cascade: Pelvic obliquity β†’ cervical spiral β†’ functional CCI

Cascade:

  • Pelvic obliquity β†’ lumbar/thoracic countercurves β†’ cervical tilt
  • Chronic subclinical neck muscle overwork β†’ premature fatigue of cervical stabilizers
  • Proprioceptive degradation at craniocervical junction β†’ functional CCI
  • Dizziness, headache, brain fog, visual disturbances

Step G4a: Cervical tilt β†’ chronic neck muscle overwork

  • Intercept: Shoe lift; Cervical bracing/taping; Ergonomic optimization
ImportantFinding: Shoe lift reduces neck pain/cervical symptoms β€” pelvic asymmetry driving cervical muscle overwork

Cervical symptoms are driven by pelvic asymmetry propagating up the kinetic chain (Gerlier Pathway 4-specific evidence). Mechanical correction at the pelvic level resolves compensatory cervical strain.

Certainty
Low
Level of action
Partial root cause β€” mechanical cervical strain

Step G4b: Proprioceptive degradation β†’ functional CCI

  • Intercept: Proprioceptive retraining; Visual-vestibular integration therapy; Low-dose aripiprazole (D2/D3 partial agonist; atypical antipsychotic at microdose)
ImportantFinding: Proprioceptive retraining works but cervical collar does NOT β€” functional CCI

The CCI is functional (proprioceptive degradation), not structural (ligamentous laxity). Treatment should focus on proprioceptive retraining, visual-vestibular integration, and neuromuscular re-education rather than surgical fusion.

Certainty
Low
Level of action
Partial root cause β€” functional CCI
ImportantFinding: Cervical collar works β€” structural CCI component

Response to external stabilization indicates a structural (ligamentous) component to the CCI, which may warrant further evaluation for surgical fusion.

Certainty
Low
Level of action
Partial root cause β€” structural CCI

5 Gerlier 4-Pathway Convergence: The Dopaminergic Node (Why Aripiprazole)

Certainty: 0.15. The 4-pathway convergence on dopamine makes this model testable. However, evidence for each upstream pathway is near-zero (cert 0.10 overall), and dopamine dysfunction is also predicted by better-supported hypotheses.

5.1 Cascade: Gerlier 4-pathway convergence at the CNS dopaminergic system:

Pathway 1 (muscle overuse) β†’ ATP drain β†’ microglial activation β†’ basal ganglia dopamine synthesis impairment Pathway 2 (sympathetic chain) β†’ NE overdrive β†’ DBH overactivity β†’ dopamine pool depletion β†’ inability to synthesize dopamine for basal ganglia and PFC Pathway 3 (nerve compression) β†’ chronic nociceptive input β†’ central sensitization β†’ microglial/astrocytic β†’ cytokine-mediated dopamine suppression Pathway 4 (functional CCI) β†’ brainstem compression β†’ ascending dopaminergic pathway disruption (VTA β†’ PFC, SNc β†’ striatum)

Step Z1: The dopaminergic convergence node

  • Intercept: Aripiprazole (low-dose, 0.25–2 mg; D2/D3 partial agonist) β€” D2/D3 partial agonist; Amantadine (dopamine releaser; NMDA antagonist); Methylphenidate (DAT/NET inhibitor; NDRI)
ImportantFinding: Aripiprazole works β€” dopaminergic node is the bottleneck

Response to D2/D3 partial agonism confirms the lesion is at or above the dopamine receptor level. The dopaminergic convergence node is rate-limiting for symptom expression.

Certainty
Low
Level of action
Partial root cause β€” dopaminergic dysfunction
ImportantFinding: Aripiprazole does NOT work β€” bottleneck below dopamine receptor

Non-response implicates a lesion below the dopamine receptor: presynaptic (dopamine synthesis, DAT function), downstream signaling (cAMP/PKA), or a non-dopaminergic Gerlier pathway (ATP depletion, autonomic/vascular, mechanical pain).

Certainty
Low
Level of action
Symptom management β€” non-dopaminergic driver

Step Z2: Distinguishing which pathway drives the dopaminergic deficit

ImportantFinding: Aripiprazole + shoe lift + midodrine all work β€” confirmed Pathway 2 (sympathetic chain)

Triple response confirms the Gerlier model: skeletal asymmetry drives sympathetic chain compression (midodrine-responsive), which is the specific pathway.

Certainty
Low
Level of action
Partial root cause — confirmed mechanical→sympathetic pathway
ImportantFinding: Aripiprazole works but shoe lift does NOT β€” non-Gerlier dopamine driver

Dopamine dysfunction is present but not driven by skeletal asymmetry. Consider Pathway 3 (nerve compression) or 4 (functional CCI), or a non-Gerlier dopamine hypothesis (neuroinflammation, GPCR AAb).

Certainty
Low
Level of action
Symptom management β€” dopamine-responsive, non-mechanical driver
ImportantFinding: Aripiprazole works AND cervical bracing works β€” Pathway 4 (functional CCI) likely

Combined dopamine response and mechanical cervical stabilization points to functional CCI as the upstream driver of dopaminergic dysfunction via brainstem compression.

Certainty
Low
Level of action
Partial root cause — functional CCI→dopamine
ImportantFinding: Aripiprazole works AND LDN works β€” shared neuroinflammatory convergence

Both D2/D3 partial agonism and TLR4 antagonism improve symptoms, suggesting neuroinflammation drives the dopaminergic deficit via microglial cytokine-mediated dopamine suppression.

Certainty
Low
Level of action
Partial root cause — neuroinflammatory→dopaminergic
ImportantFinding: Aripiprazole does NOT work but shoe lift works β€” non-dopaminergic Gerlier pathway

Gerlier drives symptoms through a non-dopaminergic mechanism: direct ATP depletion (Pathway 1), autonomic/vascular effects (Pathway 2), or mechanical pain (Pathway 3). Dopamine modulation cannot compensate.

Certainty
Low
Level of action
Partial root cause β€” non-dopaminergic mechanical driver

Step Z3: What a null aripiprazole response means A patient with documented skeletal asymmetry and aripiprazole non-response has one of: (1) ATP drain so severe dopamine modulation cannot compensate; (2) sympathetic compression β†’ cardiovascular/vascular autonomic dysfunction, not dopaminergic; (3) pain β†’ nociceptive-level, not dopaminergic, treatment needed; (4) asymmetry is present but non-contributory.

Step Z4: What a STRONG aripiprazole response means A patient with skeletal asymmetry showing dramatic improvement on low-dose aripiprazole has: (1) dopaminergic dysfunction at D2/D3 that WAS rate-limiting; (2) one or more Gerlier pathways driving dopaminergic dysfunction upstream; (3) receptors present and responsive; (4) a mechanical-pathway β†’ dopamine pathway that is testable via combination probes.

Consequence: Aripiprazole response in a patient with documented skeletal asymmetry AND positive shoe lift trial represents multi-level evidence for the Gerlier model. However, aripiprazole-positive/shoe-lift-negative patterns are also predicted by better-supported models. Diagnostic specificity comes from the COMBINATION of mechanical AND dopaminergic probes. Origin: Gerlier 2026-07-21; dopaminergic convergence tracing by mechanistic inference.